A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity

Completed · Phase 2 · Has a placebo group

Conditions studied: Weight

In brief

LIPO-102 is under evaluation for treatment of abdominal adiposity

Key facts

Study ID

NCT01180465

Run by

Neothetics, Inc

People needed

160

Starts

2010-04-01

Expected to finish

2010-09-01

Last updated by the study team

2015-03-26

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 18 - 50 years old inclusive
• Localized area of abdominal subcutaneous adiposity of Grade 3 or above on the P-PNS or C-PNS
• BMI < 25kg/m sq
• Stable diet and exercise and body weight

You may not qualify if…

• Prior treatment of abdominal subcutaneous adipose tissue
• Females within 12 months postpardum
• Known hypersensitivity to the drugs or components

Where it is running

• Study site — San Diego, California, United States
• Study site — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.